Delay, Deny, Defend on a Global Scale - Australian Insurer QBE Refuses to Pay Claims In Both the US and Australia; What's Ahead for the EU ?

"Delay, Deny Defend."  The phrase sets out the business method for too many U.S. insurers.  The phrase also is the title of an insightful and detailed book by Jay Feinman, a  Distinguished Professor of Law at Rutgers. As a law professor teaching contract law in general and insurance law in particular, Professor Feinman truly knows the subject and explains well how the phrase applies to the US insurance industry. 

Today, the phrase also applies globally. For example,  Australian insurer QBE is famous in Florida for not paying hurricane damage claims, as illustrated here, here and here.  Now, back in Australia, it's gaining fame for refusing to pay claims arising from the recent disasters in Australia. Go here for a video and print story.  In the UK, QBE  recently picked eighteen law  firms as part of its legal defense for EU claims. So, it appears  EU policyholders can look forward to the same "3D' tactics.

 

 

 

Tags:

Science and Budgets - Looking Forward, Intelligently

After eight years of President Bush blocking and denying science, current threats to science arise from tea partiers who offer mindless budget cutting generalities,  sometimes supplemented by bible thumping.  And, some offer  tax subsidies for cheap, local manufacturing, but that is not a viable long term strategy for our nation. Why? Because more and more manufacturing will be accomplished  by robots and manufacturing  "printers" that build new devices layer by layer from digital plans. Indeed, the latter  earned the February 10, 2011 cover story on the Economist (see Print me a Stradivarius). For a more local example, get a high-tech dentist and ask to watch your next dental crown being made by a mini-machine that whirs into action based on digital images of your tooth. Or, read about it here at CAD-CAM dentistry on Wikipedia.

We were not always a manufacturing nation. Indeed, we were once agrarians. Thing changed, and our nation grew and prospered. Now, society here is changing again. We are no longer the best and cheapest to make things. So, where should we be going?  Where do we have to be going?

Forward. Through science. New knowledge, new jobs, and knowledge-based products we do not yet have or even imagine. New products such as monoclonal antibodies that block diseases. They can save lives, create jobs, and reduce health care costs.

Happily, President and Mrs. Obama "get" and support the value of science. Accordingly, the President's budget promotes science and basic research. Specifics are provided by an  OMB statement that  is here on the White House website. Some key quotes are below; hat tip to Patent Docs for flagging the statement.

 Support Biomedical Research at the National Institutes of Health. The Budget includes $32 billion for basic and applied biomedical research supported by the National Institutes of Health (NIH). Innovation in this field creates and sustains companies, products, and jobs.  Through implementation of the National Center for Advancing Translational Sciences and the Cures Acceleration Network, NIH will increase its focus on bridging the translational divide between basic science and therapeutic applications. By fostering novel collaborations among government, academia, and industry, NIH will accelerate the development of treatments for diseases and disorders that affect millions of Americans. NIH will continue to pursue the leading edge of discovery in basic cancer science, development of new cancer treatments, and prevention and early detection of cancer, focusing on recent discoveries regarding cancer genomes. For Alzheimer’s disease, NIH is partnering with the private sector to find new methods for early diagnosis and to support early drug discovery and preclinical drug development. Ongoing research into environmental factors, early detection, and novel treatments will transform our understanding and care for those with autism spectrum disorders.

Increase Investment in Research and Development and Create Transformational Technologies. For many years, the United States has been a world leader in research and development (R&D) spending, as well as in the quality and impact of that spending. The challenge is for the Nation to make private and public investments in science, research and development that will keep the U.S. as the world’s leader in innovation for decades to come. The 2012 Budget does that by providing $148 billion for R&D overall, while targeting resources to those areas most likely to directly contribute to the creation of transformational technologies that can create the businesses and jobs of the future. The Budget makes progress toward the President’s commitment to double funding for key basic research agencies: the National Science Foundation (NSF), the Department of Energy’s Office of Science, and the National Institute of Standards and Technology (NIST) laboratories. These funds will be directed at priority areas, such as clean energy technologies, advanced manufacturing technologies, and cyber security. In addition, the Budget provides $12 million in NIST for the Advanced Manufacturing Technology Consortia program, a new public-private partnership that will develop road maps for long-term industrial research needs and fund research at universities, government laboratories, and businesses directed at meeting those needs.  The Budget also funds research at the National Institutes of Health with an increased focus on translating research discovering into clinical trials. These funds will directed at priority areas, such as clean energy technologies, advanced manufacturing technologies, and cyber security. The Budget also funds research at the National Institutes of Health with an increased focus on translating research discovering into clinical trials.

 Prepare 100,000 STEM Teachers over the Next Decade. Students need to master science, technology, engineering, and mathematics (STEM) in order to thrive in the 21st Century economy. Steadily, we have seen other nations gain ground in preparing their children in these critical fields. That is why the President has set the ambitious goal of preparing 100,000 STEM teachers over the next decade, and recruiting 10,000 STEM teachers over the next two years. The Budget allocates $100 million toward that goal, including $80 million from the Department of Education dedicated to teacher pathways that successfully prepare effective STEM teachers and $20 million from the National Science Foundation (NSF) to launch a new teacher-training research program called Teacher Learning for the Future. In cooperation with the Department of Education, NSF's Teacher Learning for the Future program will fund innovative efforts that design, develop, implement, and test new teacher-training programs. These programs will be developed in conjunction with a government-wide effort to improve the impact of Federal investments in math and science education by ensuring that all programs supporting K-12 and undergraduate education adhere to consistent standards of effectiveness.

Tags:

New Science, New Toxins and New Substances at Issue - Back to the Future for the So-Called Pollution Exclusions - Un Update from Business Insurance and Am Re

This week's issue of Business Insurance brings an update article on the  "pollution exclusion" - in its various iterations. The article relies in part  on this  massive Am Re summary of the case law. As more and more substances are identified as "toxins," one can expect more returns to the issues. The insurance industry also seeks to apply the clause to substances such as Chinese drywall.

The pollution exclusion arguments highlight a real problem. Insurers do not want to take any real risk, thus badly impairing the function and role of insurance.  Industry refusal to really take on risk contributes to the growing need to manage the risk that insurance does not work. 

Tags:

Chinese Government Hit With Default Judgment for Stealing Sofware Code for Use in Supressing Internet Acess

 A National Law Journal article reports that the Chinese government has been hit with a default judgment in a tort case. Through  February 16 rulings in federal court in Los Angeles,  District Judge Josephine Tucker held that Solid Oak Software Inc. was entitled to a default in a suit alleging governmental theft of software code for use in suppressing Internet access.  According to the article by Amanda Bronstad, one of the lawyers for plaintiff  is Gregory Fayer of Gipson, Hoffman & Pancione in Los Angeles.  Ms. Bronstad also reports that the Chinese government was aware of the suit, but declined to defend, as explained below:

The U.S. Department of State filed proof of service with the Chinese government on Nov. 12. But the Embassy of the People's Republic of China in the United States filed a letter with the court on Nov. 29 claiming it did not have to respond to the lawsuit. "The purpose that the Chinese Government applies and installs the Green Dam Youth Escort software is to use web filter technology to block pornographic texts and images on the internet and to protect minors from internet pornography and other dangers," the embassy wrote. "For the US company to sue China as a State, it is nothing but an uncalled for and unwarranted lawsuit."

 

 

Are Twenty Million Dead Children Enough to Illustrate the Insanity of Cutting Budgets for Science and Disease Prevention ?

Yesterday, Paul Krugman used his NYT column to tee off on the failure of the Republican budget "plan" to acknowledge that health care costs drive long-term many budget disasters, and the system is not fixing itself. The lesson really should be simple to grasp - just look at the various bankrupt car companies, or any state that can't pay its health care bills.

Some simple truths are that health care costs are enormous, and science provides ways to reduce the human losses and economic costs. For example, as is detailed below,  perhaps 20 million children across the globe have died from pneumococcal diseases easily prevented by vaccines. That stunning number is but one illustrations of the insanity of the Republican axe-wielding "budget plan"  that reduces investment in science and impoverished nations.  TSimply put, the "plan"  is economically backwards and completely lacks compassion. 

In fact, investing in science produces major returns on investment in both human and economic turns.  For example, investing in vaccines for kids overseas will save and improve lives, millions of them, thus avoiding money wasted on needless health care and all the attendant time and effort invested in caring for a profoundly sick person. And, investing in science produces jobs and other results here and abroad - someone has to make and deliver all the vaccines that are today are not made and are not delivered.

Part of the story is presented in this article from a group funded by the Gates Foundation.  The group is BIO Ventures for Global Health.  The group's leaders are birght people, and its website provides a compelling list of "neglected diseases" and opportunities for social and business progress  through a focus on opportunities related to the neglected diseases. The group describes itself with this introduction:

"The developing world is in the midst of an ongoing health tragedy. Millions of people in poor countries die every year from potentially treatable diseases—because the medicines to treat those diseases are inaccessible, outdated, unsafe, ineffective, or simply have not yet been created.

BIO Ventures for Global Health (BVGH) is a non-profit organization whose mission is to save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world. BVGH has a unique perspective – we are able to look at the health problems facing poor countries through a dual lens of expertise in both global health and the biopharmaceutical industry."

The group's entire story deserves reading and support. Here's the key statistic from one article that perhaps will provide motivation for all of us to demand intelligent budget decisions and support investing in science:

"For decades children in poor countries have received vaccines only after they had been on the market for 20 years or more; when they were off patent and thus available at commodity pricing. If you apply this standard wait time to pneumococcal disease, which kills about a million children a year, 20 million poor children would die needlessly while children in rich countries were protected by very good vaccines."

First Conviction for Corporate Manslaughter under the UK's Corporate Manslaughter and Corporate Homicide Act 2007

The UK has now seen its first criminal conviction of a corporation for homicide. CMS Cameron McKenna  provides the story in an article here at Mondaq. 

The defendant company, a small entity with only 8 employees, "was convicted of the offence of corporate manslaughter under the Corporate Manslaughter and Corporate Homicide Act 2007.  The conviction by jury follows a lengthy trial into the death of Alex Wright, a young geologist employed by the company, on 5 September 2008.  Mr Wright is believed to have died whilst investigating soil conditions in a deep trench, which collapsed and killed him."

Scientific and Political Lessons from the Tragedy of Depakote-Caused Injuries In Babies (Bracewell & Giuliani Taking on Plaintiff's Work Against Big Pharma)

Depakote. It's a drug for people with epilepsy, migraines and other miserable disease. It's also a drug that causes severe birth defects (e.g spina bifida) in a signficant percentage (perhaps 20%) of the children born to women taking Depakote during the first trimester of pregnancy.  Go here to see extracts from relevant articles. Go here to see Abbott's current, lame warning.

Science lessons from Depakote ? This drug provides yet another example of the lesson that the TIMING of the dose can be critical - e.g. during the first trimester.  That lesson was previously taught by DES daughters. Another lesson ? We need the software and smart research aimed at predicting when drugs will cause genetic problems. One more lesson ? Some drugs and "toxins" are in fact causing harm to multiple-generations by altering genes and/or the epigenome.

A political lesson ? Rudy Giuliani used to campaign in favor of  "tort reform." But now his law firm (Bracewell & Giuliani) is representing Depakote plaintiffs, as shown by this website seeking Depakote plaintiffs and using the Bracewell & Giuliani name.  And as shown by this article, the Bracewell & Giuliani firm is filing cases from around the country, in St. Clair County, the sister county to the infamous Madison County.

Welcome to the plaintiff's side, Rudy. Stay awhile  - it's  great to represent people who actually need help, and  want to hold people accountable for their actions.

__________________________________________________________________________

Go here to ontheissues for the link to a transcript with the following quotes:

Supports tort reform like “loser pays” rule
GIULIANI: Fred was the single biggest obstacle to tort reform in the US Senate. He stood with Democrats over and over again. He voted against $250,000 caps on damages, which they have in Texas. He voted against almost anything that would make our legal system fairer: loser pays rules, things that would prevent lawsuits like that $54 million lawsuit by that guy who lost his pants--you know? That cost that family $100,000 in legal fees. I think the man should have to pay the family for the $100,000. Fred Thompson, along with very few Republicans, blocked tort reform over and over and over again.

 

THOMPSON: I supported tort reform with regard to securities legislation. I supported tort reform with regard to product liability legislation, things that have to do with interstate commerce. I think it appropriately passed. I supported and worked for those things. Local issues belong at the state level. Most states have passed tort reform. That’s our system. It’s not all federalized.

Source: 2007 GOP primary debate in Orlando, Florida Oct 21, 2007
Continue Reading...

Good to See Intelligent Conservatives Speaking Out Against the Form of Government Intrusion Known as Damages Caps, a/k/a "tort reform"

The "tort reform" war cry drives me crazy. It's a meaningless set of words used - usually - in deceptive way to mask the imposition of damages caps. But the phrase sure excites the  uninformed, as illustrated by this post by Sarah Palin. Note  that Ms. Palin's post  cites as "authority" an ABA Journal article reporting that imposing liability caps reduces lawsuits. Duh - of course it does . But imposing caps on damages does not mean eliminating the "frivolous lawsuits" she says are targets. (In fact, few are frivolous - lawyers cannot afford to invest in bad claims) Instead, imposing damages caps simply makes many claims not worth suing about, and thus leaves the victims to suffer the financial loss and the pain. 

Damages caps are government intervention at its worst - protecting mistakes and shifting the value of the loss away from the doctor and the insurer, and onto the victim.  Damages caps are good for three groups  - actuaries who want certainty, insurers which want no risk, and investors in insurers who want the windfall profit created by damages capping statutes.  Damages caps are miserable and unfair to the hundreds of thousands of annual victims of medical malpractice. Sadly, the New England Journal of Medicine has studied the topic and finds that medical malpractice continues to hurt almost 18% of patients in some way. Go here for the prior post with links to the study itself, and summary information.

So, like many others, I'm glad to see Republican Senator Fred Thompson speak out and oppose the insurance industry's ceaseless cries for damages caps, which they like to call "tort reform." Fred's op-ed piece  is online  here at the Tennessean. Key excerpts are below:

"To me, conservatism shows due respect for a civil justice system that is rooted in the U.S. Constitution and is the greatest form of private regulation ever created by society. Conservatism is individual responsibility and accountability for damages caused, even unintentionally. It's about government closest to the people and equal justice with no special rules for anybody. It's also about respect for the common-law principle of right to trial by jury in civil cases that was incorporated into the Seventh Amendment to the Constitution."

***

"The legislature has made adjustments to our tort law from time to time. For example, in 2008 a law was passed requiring plaintiffs to get a written statement from a medical professional saying that the lawsuit had merit, thereby reducing medical-malpractice suits. This was reasonable and appropriate. However, never has the legislature imposed a dollar limit in cases where damages and negligence have already been proven."

 

Free ABA Help to Build a Career in Law, Science and Technology: "THE SCITECH EDGE"

The email ad below caught the eye. The topic provides something to ponder for undergrads thinking about law, as well as the lawyers thinking about a new focus.

One other idea: also learn a commercially useful language.  

 

ABA facebook linkedin 

The Section of Science & Technology Law
presents a FREE teleconference for Section members

THE SCITECH EDGE: CAREER AND BUSINESS DEVELOPMENT AT THE INTERSECTION OF LAW, SCIENCE, AND TECHNOLOGY 

WHEN: Tuesday, February 22, 2011 at 12:00pm CST

REGISTER TODAY

This 90-minute program will offer strategies and tactics to help you build your practice quickly. Join us to gain invaluable insights from these SciTech leaders: Scott Partridge (a partner at Baker Botts in Houston and 2008-2009 Section Chair), Vid Mohan-Ram, Ph.D. (an associate at Foley and Lardner in D.C., former editor/writer at Science Magazine's Next Wave, and Vice-Chair of the Section's Biotechnology Law Committee) and Kristie Prinz (founder of the Prinz Law Office in Silicon Valley and a member of the Section's Program Committee). The program moderator, Julie Fleming (founder of attorney consultancy Life at the Bar LLC, author of the 2009 book, The Reluctant Rainmaker: A Guide for Lawyers Who Hate Selling, and Secretary of the Section), will share additional perspectives based on her conversations with lawyers around the world. We’ll discuss:

·         What you must do now to grow your book of business in today’s new economy

·         How to continue your professional development, even if you’ve been in practice for years

·         Which qualifications and activities will advance your practice

·         How you can meet potential clients

·         The “must do” activities for solos and large firm lawyers for career and business development

·         Much more

You’ll leave this program with a list of bite-sized activities you can implement immediately to move your practice forward.

CLE credit is not available for this program.

CLICK HERE TO REGISTER

Your e-mail address will only be used within the ABA and its entities. We do not sell or rent e-mail addresses to anyone outside the ABA.

Update your profile | Unsubscribe | Privacy Policy

American Bar Association | 321 N Clark | Chicago, IL 60654 | 1-800-285-2221

Tags:

Collective Litigation in Latin America - An Update

This prior post noted a December 2010 collective litigation conference  co-organized by professors Manuel A. Gomez (Florida International University College of Law) and Deborah R. Hensler (Stanford Law School). The conference was the fourth in the series of international conferences on the global spread of collective litigation. The series began in 2007 at Oxford University. Comments and papers from the conference are starting to appear on-line, such as this set of comments and links from Swiss Re. Stanford's website also will host more of the papers on-line after they are all submitted in final form.

The Duty of Good Faith and Fair Dealing, and Other Laws Applicable to Sales of Products - Rules Apparently Unknown to The Epicurean Dealmaker and Various Other Global Financiers

Why do we find plainly so many immoral or amoral actions (and inaction) taken by so many of the people running some (not all) of  the top tiers of various entities in the financial sector ? The question is posed in light of  this February 5 post at The Epicurean Dealmaker (TED).  According to TED, financial instruments are just products,  and TED argues that fraud is legal when selling products,  based on the rule of caveat emptor. TED is wrong. Like many others, TED does not know the law applicable to sellling products. TED also does not know that the law of New York - and every other state -  implies a duty of good faith and fair dealing in ALL contracts, including contracts to sell products. There are no exceptions for contracts involving financiers. 

TED is who or what? TED is a fascinating blog presenting the occasional writings of an anonymous, blunt, smart banker who writes with candor and passion regarding the financial sector, and the habits and nature of  its denizens.  I usually do not respond to or quarrel with TED. To the contrary, the posts at TED are usally enjoyable and insightful (not to mention erudite and sometimes Accordingly, GlobalTort includes several  prior links and cites to TED, usually for his candid statements about the real wold ways of parts of the financial sector.  For examples,  read this post  on Goldman Sachs' self-dealing, or this one on ineffective regulation. Also enjoy this additional post on Goldman Sachs. Best of all, read my  personal favorite – TED's thoughts after the world’s best and brightest bankers told Congress they did not and could not foresee the financial fiasco.  In short, TED argued that the claimed lack of foresight was self-induced because foresight was simply not relevant to the players due to their pursuit of profit in a manner that rendered everything else immaterial and irrelevant. Of course, TED was correct. And, others  have shown that indeed the financial fiasco was in fact foreseen -  and written about - decades ago; read here.   See also this prior post on the financial sector's truly belated insight that perhaps it must think about conflicts of interest, and perhaps should even disclose them. 

Where did TED  go wrong in his latest post  ?  In some ways, it's mundane because it starts with TED once again noting  yet another admitted example of financial fraud by bankers. This time, however, TED went further and played lawyer, but not well. In short,  TED used the rest of the post to argue that fraud and half-truths are a permitted part of the process of selling "a product." According to TED, bankers are selling products and all is fair when selling " a product."   

TED's argument is wrong on the law. Way wrong. Dangerously wrong. Indeed, trial lawyers dream of events such as trying a case against TED's employer, and putting TED and his last post in front of a jury. For the financial sector, TED's writings are worse for the defendant than anything Ifrom corporate files that I've seen in almost 30 years of litigation, excluding the decades of damning tobacco documents.  

TED's legal blind spots ? To start, he apparently never learned that snake oil nake oil sales were long ago banned. TED can expand his apprecation of the law and history of product sales by reading Ann Anderson's book tracing the rise of the FDA to end snake oil sails and other acts of knowing or reckless fraud. TED might also want to read the United States Code section providing criminal penalties for fraud conducted by wire or mail. Also relevant is New York's Martin Act, a favorite of prosecutors. TED's education on fraud may then move forward to reading articles by Professor Twerski to learn that courts tossed out privity of contract limits back in the mid-century, and imposed implied product warranties far stronger than TED grasps.

As to product sales, TED also needs to learn that the 1960s brought section 402(a) of the Restatement of Torts, and its rules requiring product makers to design and warn against foreseeable harms in their products. TED probably will be shocked to know that product makers suffer liability when their product designs fail, even if the harm was not foreseeable.  Imagine if TED and his friends were actually required to pay for all the losses caused by their defectively designed CDOs and swaps. On the product liability law, Wikipedia provides the basic rules  here, For more detailed learning on the history and law of product sales, TED might profit  from  this article by Professors Henderson and Twerski, widely-known product liability gurus. 

TED also needs to understand that product makers and sellers labor under post-sale duties to warn about and/or recall defective products, and that liabnility applies to resellers of products made by others. The rules are described here in an article from Ken Ross, one of the earliest and most respected writers on  product liability prevention and planning. Under the post-sale duty rules, TED and friends should have issued warnings about their defective products, and then should have paid to take them all back. (That process is sort of underway, in some settings, as Freddie and Fannie sue the banks for selling defective CDOs, as covered here by the NYT's Dealbook, and here on GlobalTort.)

TED's education is not yet complete. To continue, perhaps an excursis on punitive damages  imposed when product makers  marketed unsafe products despite knowledge of actual or possible flaws. Today we are drowning in books  and the FCIC report detailing the many ways in which TED and his friends knew or were warned that their products were flawed, and that failure was on the horizon.  TED will not want to bear there to feel what happens if 6 or 12 average Americans are given a chance to vote on punitive damages in a trial against a large bank for most any of the frauds.

Next for TED, a lesson that the law actually does require business partners to act in good faith toward each other. For starters,  a jump to Chicago-Kent's law website  to read or watch the arguments on the appeal from the Campbell v. State Farm award of $ 145 million of punitive damages when an insurer acted in bad faith in failing to to pay a claim. That number is big enough it might even get TED's attention. (Yes, ulmately; the award was overturned as too much, but mainly because there was simply too much evidence of bad faith actions by State Farm in cases all across the country, instead of just the state involved.) 

To conclude ? A banker-focused  lesson from Judge Rakoff in a recent case and context TED can readily grasp. In short, the case arose from bankers at JP Morgan acting with exactly the kind of lack of ethics advocated by TED as they sought to achieve unfair ends but claimed they were acting within the letter of law. The case is know as Empresas, and is summariized and linked in this post by Michael Collins at the Economic Populist. Better yet, however, is Felix Salmon's post covering the opinion under the apt title: "How JP Morgan treats its clients: scandalously and in bad faith."  Unlike TED, Judge Rakoff did not excuse JP Morgan for just selling a product, and instead issued an injunction to stop JP Morgan in its tracks. The Judge's lesson for TED ? Every contract  includes "an implied promise of good faith and fair dealing."  The  news may crush TED, but it is well-settled law, even in New York.  

Why spend the time to attack TED's reasoning and post ?  Because TED's posts lovingly expose the deep flaws in too many members (not all members) of the the top tiers (by dollar volume) of the financial sector. Indeed, TED's posts are wonderful for their almost absolute candor about how business is done by global financiers.  To say the  least, the posts lovingly argue (not just admit)  that global  finance is full of very smart, very amoral individuals seeking to make enough money to retire, regardless of how it gets done.  TED's latest foray is the same - bluntly candid. And by his candor, TED illustrates exactly  why society should be actively enforcing the duty of good faith and fair dealing.  Enforcing that rule is one way to start repairing the damage caused by immoral or amoral financial engineers.  
 
_________________________________________________________________

TED's post is best read at the TED blog.  But for those who want to see the gist here, key quotes are set out below. 

But there are hybrid businesses within investment banking, as you might expect from an industry which never discovered a profit-making opportunity it didn't like. One of the most important of these is structured products, in which banks take off-the-shelf and proprietary securities and derivatives and slice, dice, and recombine them into customized instruments that they can then sell to corporations or investors. For corporate customers, these are usually marketed as the solution to some particular asset or liability management problem the company has—like, in the simplest instance, turning a fixed rate borrowing into a floating rate obligation via a fixed-to-floating swap. For (usually institutional) investors, structured products are developed to create a customized or semi-customized investment return tied to various indices, underlying securities or commodities, or almost anything under the sun an investor wants to capture. Investment banks tend to be really good at creating structured products, both because they understand the underlying financial instruments and markets as well or better than anyone and because they have hired a raft of really, really smart propeller heads from academia and elsewhere who can manipulate the complicated maths required to structure them.

But look very, very carefully at the preceding description, O Dearly Beloved, and see if you can detect the pivotal distinction. Did you see it? Did you catch the sleight of hand?

But of course you did, because you are so clever. Structured products are just that: customized products, that are manufactured, marketed, and sold to customers. Now they may in fact be (and usually are) sold as solutions to some problem or opportunity the customer wants to address, but they are products nevertheless. And this bears crucially on the proper understanding of the relationship and obligations between the bank which creates and sells them and the customer which purchases them.
                                                                                    ***

But in structured products, we are talking about manufactured goods. The bank purchases the raw materials for a trade, creates a structure around these components which delivers a certain advertised set of performance behaviors and characteristics, and sells them to its customer. It sells a product. Accordingly, the customer which purchases a structured product from an investment bank is no more a "client" of that bank—benefiting from a trusted fiduciary advisory relationship—than I am when I buy a can of soda or an automobile. Now it's true that both regulation and norm require that the seller of a manufactured product deliver a good which performs as advertised, and which does not cause unforseen harm or adverse consequences. But Coca Cola or General Motors do not owe me, as the purchaser of their products, any sort of fiduciary obligation or particular duty of care.1

Investment banks are guilty of blurring this distinction themselves, by casually insisting on using the term "client" to describe almost every entity they transact with, whether it is an M&A advisee or the purchaser of a forward start swap. But we are not alone in doing this. Remember the first time you went to look at houses or apartments with a real estate broker, and he or she called you a valued client? Do you also remember how soon you discovered that real estate brokers work for the seller or landlord, who are their real clients, and that you were just a sucker patsy customer? But no matter the particular circumstances, the economic and transactional roles are clear: if someone is selling you a product or a "solution," you are not a client. You are a customer.

And customers do not usually have the right or the ability to see into a seller's manufacturing process to see how the sausage gets made, what type and quality of ingredients are used, and whence the various sources and magnitudes of the resulting profit margin come. I don't know the kind and cost of ingredients that go into my Diet Coke, or the source and cost of the wiring harness in my Range Rover. Do you? Of course not. Manufacturers manufacture things to make a profit. The magnitude and source of that profit is, for me as a consumer, not even a secondary concern. My concern is to get a reasonable quality product which satisfies my needs for the best possible price.

I can try to mitigate the fundamental information asymmetry between the manufacturer of a product and me as buyer in one of two basic ways: I can try to educate myself about the product, and become a more sophisticated consumer, or I can set the seller up in price competition with one or more other sellers to get a better price. Both of these approaches become more difficult for structured products the more customized the product or solution at hand is. And both of these approaches are resisted heartily by the manufacturer, whether it be an investment bank, a soda pop company, or an auto OEM. (Since when did you see any business offer to forgo profits on its activities?) Unless a consumer can manufacture the good she requires herself, she is ineluctably at the mercy of the seller, mitigated only by her negotiating skills.

 

* * *

So count me among the distinctly underwhelmed and non-outraged over Mr. Rosen's tale of woe. Show me examples of for-profit manufacturers that cheerfully offer their customers complete visibility on all their embedded sources of profit, or who refrain from a little game of hide and seek with customers who press them. The information games Mr. Rosen relates arise exactly because some investment bank customers try to become more sophisticated about their purchases, in order to increase their negotiating leverage over price. Some clients are indeed very sophisticated, and those tend to get the best terms and the best price. Most customers are not; they are price takers. But that is true of any market.

I strenuously disagree with anyone who contends that apologists like me are trying to "retroactively apply caveat emptor principles" to this corner of the financial markets. They have always been in effect here. It is only the foolish and incompetent customer who did not realize it. I would like some of the self-appointed defenders of Corporate America or the assembled hedge funds and pension fund investors in the structured products market to go toe-to-toe with these alleged "victims" over the terms and price of a moderately structured security or derivative. Most Treasurers or portfolio managers I know would kick their asses six ways from Sunday. These are not dumb, lily-livered creampuffs who buy our stuff.

 

 

Contingent Liabilty Segregation and Estimation - FASB Dithers While Bank of America Seeks to Take Charges and Move On

Saying other things are more important, FASB continues to dither on estimating contingent liabilities - see here and this brief but biting story with some great quotes at the end about FASB's delays. The low priority assigned to contingent liabilities is especially hard to understand in this age of massive corporate bankruptcies by companies which failed to reserve for future liabilities (e.g. car companies), not to mention massive frauds and/or miserable business practices. 

The topic of coping with contingent liabilities continues to crystallize for Bank of America. This week it moved forward by pushing bad mortgages into a "different" business unit (but not entity), and by selling its forced place insurance business (Balboa) to QBE, an Australian insurer. The stories are everywhere, but good ones are here and here at the NYT. These steps follow massive December and January billion dollar settlements with Fannie Mae and Freddie Mac for, in essence, fraud by Countrywide in its mortgage business. Meanwhile, lots of others are lining up and suing  the banks for selling bad mortgages, including Allstate.

Morals to the story ?

  • Contingent liabilities matter, and should be fully disclosed. FASB's delays are disappointing, at best.
  • Segregating liabilities and claims is perceived as desirable to take the stock market's eye off of liabilities and problems.
  • Too many masters of the universe create giant messes for millions of people, but then want to take an accounting  charge and walk way.

One more note. Insurance companies, such as Allstate, constantly complain there is too much litigation by plaintiffs. But when their money is stake, Allstate is happy to be a plaintiff, as evidence by its suit against Bank of America. Actions speak louder than words.

 

 

World Cancer Day - Will Lawyers Speak Out and Demand Better from Our Nations ?

 

February 4 is the day the World Health Organization (WHO) designates as World Cancer Day.  According to WHO, "an estimated 84 million people will die of cancer between 2005 and 2015 without intervention."  As the American Cancer Society explains, the day will be commemorated in the US by the Empire State Building lighting its top in the orange and blue colors chosen to signify the day.

The costs of cancer are massive. In terms of human suffering, there are no words I know to state the vast scale of the pain and fear caused by cancer. On objective data, the numbers are stunning in financial terms. In just the US, the costs are currently at over $ 100 billion per year, and in 2020 will be an estimated $ 158 billion per year. In global terms, the annual direct and indirect cost are estimated  $1.5 -2 trillion (yes, that's with a t, and every year.) Those numbers, however, do not seem to grab enough attention and cause nearly enough demands for "better." So, for today, a post to try to bring the subject of cancer closer to the financial and emotional hearts of lawyers.

Consider the lesson on cancer that can be learned from the collapse of  Howrey,  a major US law firm with some international offices.  Anyone who follows "big-law" at all knows that Howrey is in trouble. An AmLaw  story on Wednesday  reminded me of this prior article about Howrey's woes and a link to cancer. According to that article, part of Howrey's troubles tie back  to two of its most  trusted partners dying of cancer   -   before age 60. What a tragic waste.  The key text is pasted far below in bold.

For World Cancer Day, let's personalize a question to our profession:  when are our American lawyers -  and our global brethren -  going to become really outraged about cancer and demand better from our nations ?  We are advocates;  we know how to speak and be heard. So, let's speak out. 

To whom can we speak? To our families, our friends, our partners and associates, and to our governments.  But do not worry to much about the specific audience - just  speak.  Creating changerequires social networking and reaching a Tipping Point of the sort so eloquently described by Malcolm Gladwell in his book, Tipping Point.  And,  know that there is a receptive audience in place. How so? Sadly (or, perhaps, wonderfully), the reality is that  4% of Americans (that's about 10-15 million Americans) are cancer survivors, and so have  "pre-existing conditions".  At the very least, go here to sign a global petition to demand more attention to cancer research and prevention. Prevention is too little mentioned, but is as key as research for existing cancers.

Need more data to help you advocate? The above numbers  are stunning, but sadly there are many more compelling numbers numbers available for advocacy. Disease specific numbers, and much more data, can be found  through the American Cancer Society's web pages devoted to statistics.  The 2010 summary is here. For global numbers, go here.

The US numbers ?  500,000 Americans die of cancer every year. On top of the deaths, 1.5 million Americans are diagnosed every year with cancer. In a decade, that rate of diagnoses is about equal to cancer hitting everyone in the cities (not burbs) of NY, LA and Chicago. And that of course includes all the lawyers in those cities.

Global numbers? Over 7.5 million annual cancer deaths. Over 12 million cancers found, every year.

More personal numbers?   Ultimately, cancer will hit 1 in 3 American women, and 1 in 2 American men. And, there are increasing signs that environmentally-induced cancers can become multi-generational. Think DES daughters. For disturbing visual evidence, go here and link to the Vanity Fair story on apparent generations of victims of Agent Orange.  Or, consider the issues raised regarding the effects of  exposure to  BPA and pregnancy. How and why may a toxic exposure cause multi-generational cancers ? Those answers are not completely clear yet, but they probably involve epigentics, including chemically-caused changes to the epigenome, a structure that sits above each genome.

Lawyers should know how to pull at hearts.  To reach hearts and minds, help people learn and feel that every 10 minutes, someone in the US dies from a blood cancer. And, they are too often children. Help them see and feel the human and financial pain and loss inherent in the steadily increasing rates of cancer in kids  The data show an increase of about 2% per year, FOR EVERY YEAR SINCE 1974. Help others see the faces and families behind the datapoints.

Need more? Go here for a heartbreaking video. It's the story of the Beads of Courage awarded to some kids with cancer. It's a powerful reason to ask what we might achieve if we at least doubled or tripled our miserly national investment of $ 5 billion in cancer research. 

Cynical about more money making a real difference ? Don't be. Go here to read about St. Jude's current project to sequence the genes inside 600 cancers they've culled from children over the years:  The key quote: "This is the largest and most powerful single initiative in the 50-year history of St. Jude," the research hospital's director, Dr. William E. Evans, said at a press briefing announcing the project .... "DNA is being sequenced as we speak," he added.

Need more reason for optimism?  Consider this 2010  NYT op-ed article by Dr. James Watson of DNA fame. He said:

"THE National Cancer Institute, which has overseen American efforts on researching and combating cancers since 1971, should take on an ambitious new goal for the next decade: the development of new drugs that will provide lifelong cures for many, if not all, major cancers. Beating cancer now is a realistic ambition because, at long last, we largely know its true genetic and chemical characteristics. (emphasis added)

This was not the case when President Richard Nixon and Congress declared a “war on cancer” more than 35 years ago. As a member of the new National Cancer Advisory Board, I argued that money for “pure cancer research” would be a more prudent expenditure of federal funds than creating new clinical cancer centers. My words, however, fell on deaf ears, and the institute took on a clinical mission. My reward for openly disagreeing was being kicked off the advisory board after only two years."

Given the numbers and the science, where are the  reasoned but passionate demands that our governments do much more to stop the damn cancers that are killing millions of our loved ones, and too many of our partners and friends ? C'mon lawyers, use your gifts of persuasion and speak out.   You may help to save your law firm from a Howrey-like collapse. You also might save the life of your child, your spouse, or your partner.  

_________________________________________________________________

"Several former partners say that communication, which has never been the firm's strong suit, became a much greater issue after the sudden deaths of two respected and independent members of the executive committee--deaths that coincided with a major slowdown in work. In June 2008 vice-chairman Mark Wegener, the firm's global litigation cochair, died of cancer at 59; 11 months later, IP cochair Cecilia Gonzalez, also a vice-chair, succumbed to cancer at 53. Gonzalez, a huge rainmaker, was "always willing to introduce you to her clients," recalls one partner. And Wegener "would always call you back right away," notes another--giving partners a sense their concerns were being heard and transmitted to Ruyak." 

Tags:

Science Looks at Massive Storms - The US Blizzard of 2011, and Cyclone Yasi

Over the last couple of days, Chicago received 15-20 inches of snow from a massive storm spread across most of North America. For some great s images of its breadth, go here or here. For the very local view of my front entry, see above. Happily, the snow is really not a big deal for the well since our area has plenty of snow plows that work wonders if everyone has the brains to stay ofdf the roads for a day.

The storm here is a lightweight to cyclone Yasi that hit Australia with 155 mph winds. Go here for stunning images from the satellites, and more data than any one human can digest. Australia certainly has had a tough 2011 weather-wise.

 

Tags:

Cigarettes Can Get Worse - Blackmarket Brand Includes Asbestos and Chinese Drywall

Apparently black marketeers from  Russia can beat out big tobacco in the race to the bottom. Go here for the story and a picture of the contraband Jin Ling cigarettes.

Tags: